Abstract
Oral treatment of simple urinary tract infections generally involves 5 to 7 days of antibiotic therapy. This study with enoxacin, a new antibacterial agent of the quinolone-azaquinolone class, investigated the efficacy of a single dose compared with 3 days of treatment. A total of 154 outpatients with symptoms of simple cystitis were treated in an open randomized study with enoxacin, either one 600-mg dose or 200 mg twice a day for 3 days. A urine sample was collected for culture before treatment, 7 to 10 days after treatment, and 4 to 6 weeks after treatment. Seventy-three patients had positive bacterial cultures from the pretreatment urine sample; the predominant pathogen was Escherichia coli, along with a number of other gram-negative organisms and Staphylococcus spp. Of these patients, 33 received a single dose of enoxacin and 40 were treated for 3 days. Follow-up examination at 7 to 10 days showed negative urine cultures in 76% of patients from the single-dose group and 89% from the multiple-dose group, a difference that was not statistically significant (P = 0.665, Fisher's exact test). A number of patients were lost to follow-up at 4 to 6 weeks. However, of those who did attend, only three patients were shown to have relapsed or become reinfected (two in the multiple-dose group and one in the single-dose group). Enoxacin was well tolerated in both groups of patients; the few adverse events were mostly mild.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bauernfeind A., Ullmann U. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):33–38. doi: 10.1093/jac/14.suppl_c.33. [DOI] [PubMed] [Google Scholar]
- Davies B. I., Maesen F. P., Teengs J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):83–89. doi: 10.1093/jac/14.suppl_c.83. [DOI] [PubMed] [Google Scholar]
- Duncan I. B., Skulnick M., Marshall P. W. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):1–6. doi: 10.1093/jac/14.suppl_c.1. [DOI] [PubMed] [Google Scholar]
- Fair W. R., Crane D. B., Peterson L. J., Dahmer C., Tague B., Amos W. Three-day treatment of urinary tract infections. J Urol. 1980 May;123(5):717–721. doi: 10.1016/s0022-5347(17)56104-2. [DOI] [PubMed] [Google Scholar]
- Gleckman R. A. Treatment duration for urinary tract infections in adults. Antimicrob Agents Chemother. 1987 Jan;31(1):1–5. doi: 10.1128/aac.31.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gossius G., Vorland L. A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women. Scand J Infect Dis. 1984;16(4):373–379. doi: 10.3109/00365548409073963. [DOI] [PubMed] [Google Scholar]
- Greenberg R. N., Reilly P. M., Luppen K. L., Weinandt W. J., Ellington L. L., Bollinger M. R. Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women. J Infect Dis. 1986 Feb;153(2):277–282. doi: 10.1093/infdis/153.2.277. [DOI] [PubMed] [Google Scholar]
- Hooton T. M., Running K., Stamm W. E. Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin. JAMA. 1985 Jan 18;253(3):387–390. [PubMed] [Google Scholar]
- Iravani A., Pryor N. D., Richard G. A. Treatment of urinary tract infections with varying regimens of sulfisoxazole. J Urol. 1983 Sep;130(3):484–487. doi: 10.1016/s0022-5347(17)51263-x. [DOI] [PubMed] [Google Scholar]
- Rubin R. H., Fang L. S., Jones S. R., Munford R. S., Slepack J. M., Varga P. A., Onheiber L., Hall C. L., Tolkoff-Rubin N. E. Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. JAMA. 1980 Aug 8;244(6):561–564. [PubMed] [Google Scholar]
- Siporin C., Towse G. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):47–55. doi: 10.1093/jac/14.suppl_c.47. [DOI] [PubMed] [Google Scholar]